2.12  0.24 (12.77%)		03-31 16:00
Open: 2.06 High: 2.28 Volume: 40,626		Pre. Close: 1.88 Low: 2.06 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	3.03	1-year :	3.59
Resists	First :	2.6	Second :	3.07
Pivot price	2.46
Supports	First :	1.82	Second :	1.52
MAs	MA(5) :	2.22	MA(20) :	2.54
	MA(100) :	2.87	MA(250) :	12.81
MACD	MACD :	-0.2	Signal :	-0.1
%K %D	K(14,3) :	13.6	D(3) :	12
RSI	RSI(14): 35.8
52-week	High :	30.79	Low :	1.82

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NCEL ] has closed above bottom band by 14.3%. Bollinger Bands are 58.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.28 - 2.29	2.29 - 2.3
Low:	2.04 - 2.05	2.05 - 2.06
Close:	2.1 - 2.12	2.12 - 2.14

NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.

Mon, 09 Mar 2026
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - PR Newswire

Mon, 09 Mar 2026
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - ChartMill

Thu, 29 Jan 2026
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences - PR Newswire

Tue, 04 Nov 2025
NewcelX outlines clinical development roadmap for neurodegenerative therapies - Investing.com

Mon, 03 Nov 2025
NewcelX (Nasdaq: NCEL) shares strategic roadmap; investor presentation live post NLS merger - Stock Titan

Mon, 03 Nov 2025
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	5 (M)
Shares Float	2 (M)
Held by Insiders	71.3 (%)
Held by Institutions	4.1 (%)
Shares Short	36 (K)
Shares Short P.Month	107 (K)

EPS	-6.62
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-11.28
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-155.2 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	37 (M)

PE Ratio	-0.33
PEG Ratio	0
Price to Book value	-0.19
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.